Comparing available JAK inhibitors for treating patients with psoriasis

References

• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May 28;369:m1590.
   PubMedGoogle Scholar
• Jankowiak B, Kowalewska B, Krajewska-Kułak E, et al. Stigmatization and quality of life in patients with psoriasis. Dermatol Ther (Heidelb). 2020 Apr;10(2):285–296.
   PubMed Web of Science ®Google Scholar
• Kowalewska B, Jankowiak B, Cybulski M, et al. Effect of disease severity on the quality of life and sense of stigmatization in psoriatics. Clin Cosmet Investig Dermatol. 2021 Feb 2;14:107–121.
   PubMed Web of Science ®Google Scholar
• Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021 Feb 16;15:39–51.
   PubMedGoogle Scholar
• Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020 Feb;10(1):29–42.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read CP. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19; 323(19):1945–1960.
   PubMed Web of Science ®Google Scholar
• Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021 May;21(3):170–173.
   PubMed Web of Science ®Google Scholar
• Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm. 2004 Jul-Aug;10(4):318–325.
   PubMedGoogle Scholar
• Weigle N, McBane SP. Am fam physician. American Family Physician. 2013 May 1;87(9):626–633.
   PubMedGoogle Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020 Oct 11; 21(20):7488.
   Web of Science ®Google Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020 Mar;80:106210.
   PubMed Web of Science ®Google Scholar
• Kim HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch Pharm Res. 2020 Nov;43(11):1173–1186.
   PubMed Web of Science ®Google Scholar
• Padda IS, Bhatt R, and Parmar M. Tofacitinib. 2022 Jan 6. StatPearls. Internet Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572148/
   Google Scholar
• Xeljanz, and Xeljanz XR. (tofacitinib) [package insert]. New York NY: Pfizer, Inc. 2021; Revised 12/2021
   Google Scholar
• Chen M, Dai SM. A novel treatment for psoriatic arthritis: janus kinase inhibitors. Chin Med J (Engl). 2020 Apr 20;133(8):959–967.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec 28 17(1):78.
   PubMed Web of Science ®Google Scholar
• Rinvoq (upadacitinib) [package insert]. North Chicago: IL: AbbVie Inc. 2021; Revised 12/2021
   Google Scholar
• Tegtmeyer K, Ravi M, Zhao J, et al. Off-label Studies on the Use of Ruxolitinib in Dermatology. Dermatitis. 2021 May-Jun 01 32(3):164–172.
   PubMedGoogle Scholar
• Tegtmeyer K, Zhao J, Maloney NJ, et al. Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat. 2021 Jun;32(4):399–409.
   PubMed Web of Science ®Google Scholar
• Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019 Aug 9; 10:1862
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017 Apr;77(5):521–546.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019 Nov;30(7):648–658.
   PubMed Web of Science ®Google Scholar
• Krueger J, Clark JD, Suárez-Fariñas M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016 Apr;137(4):1079–1090.
   PubMed Web of Science ®Google Scholar
• Fitz L, Zhang W, Soderstrom C, et al. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol. 2018 Oct;43(7):790–797.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019 Apr 16; 50(4):892–906.
   PubMed Web of Science ®Google Scholar
• Bagherani N, Smoller BR. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis. Dermatol Ther. 2017 May;30(3):e12467.
   Web of Science ®Google Scholar
• Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013 Jul;169(1):137–145.
   PubMed Web of Science ®Google Scholar
• Ports WC, Feldman SR, Gupta P, et al. Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design. J Drugs Dermatol. 2015 Aug;14(8):777–784.
   PubMed Web of Science ®Google Scholar
• Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016 Oct 3 16(1):15.
   PubMedGoogle Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012 Sep;167(3):668–677.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Tan H, et al. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol. 2014 Mar;13(3):252–256.
   PubMed Web of Science ®Google Scholar
• Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015 Apr;26(2):121–123.
   PubMed Web of Science ®Google Scholar
• Bushmakin AG, Mamolo C, Cappelleri JC, et al. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015 Feb;26(1):19–22.
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015 Aug 8 386(9993):552–561.
   PubMed Web of Science ®Google Scholar
• Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol. 2016 Aug;43(8):869–880.
   PubMed Web of Science ®Google Scholar
• Abe M, Nishigori C, Torii H, et al. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial. J Dermatol. 2017 Nov;44(11):1228–1237.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tsai TF, Lee MG, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci. 2017 Oct;88(1):36–45.
   PubMed Web of Science ®Google Scholar
• Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017 Jul;77(1):79–87.e1.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct;173(4):949–961.
   PubMed Web of Science ®Google Scholar
• Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018 Oct;179(4):853–862.
   PubMed Web of Science ®Google Scholar
• Menter MA, Papp KA, Cather J, et al. Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised Phase 3 Trials. J Drugs Dermatol. [2016 May 1];15(5):568–580.
   PubMed Web of Science ®Google Scholar
• Hutmacher MM, Papp K, Krishnaswami S, et al. Evaluating dosage optimality for tofacitinib, an oral janus kinase inhibitor, in plaque psoriasis, and the influence of body weight. CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):322–330.
   PubMedGoogle Scholar
• Mamolo C, Harness J, Tan H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014 Feb;28(2):192–203.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Thaçi D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Dec;75(6):1162–1170.e3.
   PubMed Web of Science ®Google Scholar
• Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1753–1759.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Vender R, Sofen H, et al. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):323–332.
   PubMed Web of Science ®Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434–447.
   PubMed Web of Science ®Google Scholar
• Page KM, Suarez-Farinas M, Suprun M, et al. Molecular and cellular responses to the TYK2/JAK1 Inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis. J Invest Dermatol. 2020 Aug;140(8):1546–1555.e4.
   PubMed Web of Science ®Google Scholar
• Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020 Dec;140(12):2359–2370.e5.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016 Jun;174(6):1266–1276.
   PubMed Web of Science ®Google Scholar
• Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2018 Jul;179(1):54–62.
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 Trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018 Oct 4 379(14):1313–1321.
   PubMed Web of Science ®Google Scholar
• Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015 Sep;173(3):767–776.
   PubMed Web of Science ®Google Scholar
• Ludbrook VJ, Hicks KJ, Hanrott KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985–995.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luchi M, Fidelus-Gort R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat. 2016 Aug;27(4):332–338.
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012 Oct;67(4):658–664.
   PubMed Web of Science ®Google Scholar
• Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015 Oct;173(4):989–997.
   PubMed Web of Science ®Google Scholar
• Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022 Jan;86(1):148–157.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19 377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017 Oct 19 377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019 Jan 11 5(1):e000808.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019 Jan 11 5(1):e000806.
   PubMed Web of Science ®Google Scholar
• Xie R, Deng C, Wang Q, et al. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
. Int J Clin Pharmacol Ther. 2019 Sep;57(9):464–473.
   PubMed Web of Science ®Google Scholar
• Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018 Oct 29 20(1):242.
   PubMedGoogle Scholar
• van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline c-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019 Sep;46(9):1089–1096.
   PubMed Web of Science ®Google Scholar
• Mc Ardle A, Flatley B, Pennington SR, et al. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. 2015 Jun 1 17(1):141.
   PubMedGoogle Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020 Oct 15 383(16):1511–1521.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021 Apr 1 384(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021 Oct;7(3):e001838.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled Phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021 Jun;8(2):903–919.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020 Dec 3 80(3):312–320.
   Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1 392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar
• Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford). 2020 Jul 1 59(7):1495–1504.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of pf-06700841 in subjects with active psoriatic arthritis - study results - clinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2021.
   Google Scholar
• Efficacy and safety of BMS-986165 compared with placebo in participants with active psoriatic arthritis (PsA) - study results - clinicalTrials.gov Bethesda (MD): National Library of Medicine (US). 2021.
   Google Scholar
• Mease PJ, Deodhar A, Van der Heijde D, et al. POS0198 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021;80:314–315.
   Web of Science ®Google Scholar
• Vyas D, O’Dell KM, Bandy JL, et al. Tofacitinib: the First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2013 Nov;47(11):1524–1531.
   PubMed Web of Science ®Google Scholar
• FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) [Internet]. U.S. Food and Drug Administration; 2019 [cited 2022 Jan 10]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and
   Google Scholar
• Aschenbrenner DS. Tofacitinib receives new boxed safety warning. Am J Nurs. 2019 Nov;119(11):20.
   Web of Science ®Google Scholar
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF). Inhibitor in subjects with rheumatoid arthritis - study results - clinicaltrials.gov. Bethesda (MD): National Library of Medicine (US). 2021.
   Google Scholar
• Rajasimhan S, Pamuk O, Katz JD. Safety of Janus Kinase Inhibitors in Older Patients: a Focus on the Thromboembolic Risk. Drugs Aging. 2020 Aug;37(8):551–558.
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020 Nov;79(11):1400–1413.
   PubMed Web of Science ®Google Scholar
• FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. U.S. Food and Drug Administration; 2021 [cited 2022 Jan 10]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death
   Google Scholar
• Strober B, Buonanno M, Clark JD, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013 Nov;169(5):992–999.
   PubMed Web of Science ®Google Scholar
• Valenzuela F, Papp KA, Pariser D, et al. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol. 2015 May 8 15(1):8.
   PubMedGoogle Scholar
• Assessment report: jyseleca. domenico scarlattilaan 6, 1083 HS Amsterdam, The Netherlands: European Medicines Agency; 2020. ( Procedure No. EMEA/H/C/005113/0000).
   Google Scholar
• The Lancet R. Arthritis and fertility: time to think about men. Lancet Rheumatol. 2021;3(10):e671.
   Google Scholar
• Gilead receives complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis [media release] [Internet]. Gilead Sciences, Inc; 2020 Aug 18; Available from: https://investors.gilead.com/news-releases/news-release-details/gilead-receives-complete-response-letter-filgotinib-treatment
   Google Scholar
• Study to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis - full text view - clinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2021.
   Google Scholar
• Study to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease - full text view - clinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2021.
   Google Scholar
• Dillon KL. A Comprehensive literature review of jak inhibitors in treatment of alopecia areata. Clin Cosmet Investig Dermatol. 2021 Jun 25; 14:691–714
   PubMed Web of Science ®Google Scholar
• Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019 Jun;11(8):737–754.
   PubMed Web of Science ®Google Scholar
• Opzelura (ruxolitinib) [package insert]. Wilmington: DE: Incyte Corporation. 2021; Revised 09/2021
   Google Scholar